Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

CCR Translations

Getting Personal with Melanoma

Helen Heslop
Helen Heslop
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-11-0841 Published July 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Long-term follow-up of patients with metastatic melanoma who received adoptive immunotherapy with autologous tumor infiltrating lymphocytes shows that patients who attained complete remission had durable responses, with 19 of 20 such patients remaining in remission from 3 to 7 years or more. Clin Cancer Res; 17(13); 4189–91. ©2011 AACR.

Commentary on Rosenberg et al., p. 4550

In this issue of Clinical Cancer Research, Rosenberg and colleagues (1) provide long-term follow-up data on 93 patients with metastatic melanoma who received personalized therapy for their disease, which took the form of infusions of autologous tumor-infiltrating lymphocytes (TIL) after lymphodepletion. They describe three sequential clinical trials in which they progressively increased the intensity of the lymphodepletion regimen by addition of higher doses of total body irradiation to a chemotherapy backbone of fludarabine and cyclophosphamide. The initial reports of outcomes of these studies have been previously published, but this article now describes the results obtained at a median follow-up of 62 months. The increasing intensity of lymphodepletion was associated with increasing objective and complete response (CR) rates (from 49% to 72% and 12% to 40%, respectively). Of particular note, 19 of the 20 patients who attained CR have remained in remission from 3 to 7 years or more (1). This long-term CR rate is particularly impressive given that the trials targeted high-risk populations in which many patients had been heavily pretreated and had visceral metastases at the time of T-cell infusion.

The above results show that adoptive T-cell immunotherapy can produce durable disease control. This effect has also been observed in other studies of T-cell immunotherapy, including donor lymphocyte infusion to treat relapse after allogeneic hematopoietic stem cell transplant (2), infusion of cytotoxic T lymphocytes targeting lymphoma or nasopharyngeal cancer (3–6), and in one patient with melanoma treatment with autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1 (7). In the TIL studies reported here, factors associated with objective response included longer telomeres of the infused cells, the number of CD8+ CD27+ cells infused, and the persistence of the infused cells in the circulation at 1 month (1). Rosenberg and colleagues do not provide data on the longer-term persistence of infused cells; however, studies using genetically modified T cells have shown persistence for up to a decade (3, 8), which may contribute to long-term disease control.

Until March 2011, dacarbazine and interleukin-2 were the only two agents that had been approved by the U.S. Food and Drug Administration (FDA) for the therapy of melanoma. However, in the last year, two significant studies of new agents targeting this disease were published, and one resulted in approval of another agent. PLX4032, an inhibitor of mutated BRAF (9), has produced an impressive response rate: 26 of the 32 patients treated at the recommended phase II dose had an objective response (81%), although only 2 of these patients had a CR. These responses, however, were often not complete (2/26 CR) or completely durable, although the median duration of progression-free survival (>7 months) had not been reached at the time the data were submitted for publication. Ipilimumab, a monoclonal antibody against the inhibitory lymphocyte receptor CTLA-4, which downregulates pathways of T-cell activation, also has activity in melanoma. Patients with metastatic melanoma were randomly assigned to receive ipilimumab alone or in combination with a glycoprotein 100 peptide vaccine or the vaccine alone (10). There was an objective response rate of 7% in the 540 patients who received one of the two ipilimumab-containing regimens, but responses to ipilimumab continued to improve for several months, and a significant proportion of these patients maintained an objective immune response for more than 2 years (10). Moreover, improvements in both overall survival and progression-free survival were seen in the patients who received anti–CTLA-4 therapy compared with control patients who received only the vaccine. The median overall survival was 10.0 months in patients who received ipilimumab plus the vaccine and 10.1 months in those who received ipilimumab alone, compared with 6.4 months in patients who received only the vaccine. Based on these results, the FDA approved the use of ipilimumab to treat patients with late-stage (metastatic) melanoma on March 25, 2011.

The observation that sustained CRs can be achieved both by infusion of TILs and administration of ipilimumab supports the contention that immune modulation can effectively control disease in at least a subset of patients with advanced melanoma. Therapy with TILs is not an option for all patients with metastatic melanoma, because manufacture of this product requires both that a suitably sized tumor lesion is accessible for resection to obtain TILs and that a cell product can be generated by ex vivo culture and expansion, a requirement that is currently met by approximately 45% of patients with metastatic melanoma (1). The manufacturing protocols for TIL generation are exportable to other institutions (11) and have been facilitated by recent changes in manufacturing that incorporate newer cytokine and costimulatory molecule technology in improved bioreactors. A recent white paper proposed a randomized multicenter study of TIL therapy. For this study to be feasible, investigators will need to develop a consensus about the optimal lymphodepletion regimen and control group, define manufacturing processes, and decide on the postinfusion cytokine support (11). Given the sustained CRs described in this report, the development and design of such a study should be a priority.

The long-term benefit of TIL infusions described in this report also justifies exploration of other T-cell therapy approaches in patients with metastatic melanoma. Figure 1 summarizes T-cell strategies that are currently undergoing clinical testing. Several investigators have described a methodology for generating CD8+ or CD4+ antigen-specific T-cell clones by stimulating responding T cells with antigen-presenting cells pulsed with peptides derived from tumor antigens expressed by melanoma cells (7). An alternative strategy is to genetically modify nonspecifically activated T cells with artificial receptors specific for tumor antigens. The National Cancer Institute group has identified T-cell receptors (TCR) that are highly reactive to melanoma/melanocyte antigens from screens in immunized transgenic mice and from cloning TIL lines, and undertaken clinical trials in which these TCRs are transferred to activated peripheral blood lymphocytes (8). Objective response rates of 19% to 30% have been reported (8). An alternative strategy is to transduce T cells with chimeric antigen receptors consisting of an antigen-binding exodomain and a T-cell signaling endodomain so that the antigen specificity of an antibody and the cytotoxic properties of a T cell are combined in a single fusion molecule. Preclinical studies have evaluated the nonprotein tumor antigen disialoganglioside 2 (GD2) because it is expressed by the majority of melanoma cells and cannot be targeted by conventional TCRs (12). For individuals in whom TIL manufacture fails or TIL infusions do not produce clinical benefit, adoptive immunotherapy with such other T-cell products may be considered.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

T-cell therapies that target melanoma. A, tumor may be harvested, and TILs harvested and cultured for subsequent infusion into the patient. B, peripheral blood mononuclear cells may be genetically modified with a chimeric antigen receptor (CAR; shown) or a TCR specific for an antigen expressed by tumor cells. C, peripheral blood mononuclear cells (PBMC) may be stimulated with peptides derived from a tumor antigen expressed on antigen-presenting cells to generate T-cell clones that recognize tumor antigens.

All the above adoptive T-cell therapies may be further improved by combining them with antibodies that target downregulators of T-cell activation, such as CTLA-4, or block other negative regulators of immune function, such as PD1, or immunosuppressive cells and cytokines in the tumor microenvironment. In the longer term, the optimal personalized therapy for melanoma may be to combine therapies that act by different mechanisms. For example, it may be possible to combine T-cell immunotherapy approaches directed to melanoma antigens with targeted small molecules that inhibit aberrantly activated pathways in the individual's tumor.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • Received April 19, 2011.
  • Accepted April 26, 2011.
  • ©2011 American Association for Cancer Research.

References

  1. 1.↵
    1. Rosenberg SA,
    2. Yang JC,
    3. Sherry RM,
    4. Kammula US,
    5. Hughes MS,
    6. Phan GQ,
    7. et al.
    Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res 2011;17:4550–7.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Kolb HJ
    . Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112:4371–83.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Heslop HE,
    2. Slobod KS,
    3. Pule MA,
    4. Hale GA,
    5. Rousseau A,
    6. Smith CA,
    7. et al.
    Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115:925–35.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Louis CU,
    2. Straathof K,
    3. Bollard CM,
    4. Ennamuri S,
    5. Gerken C,
    6. Lopez TT,
    7. et al.
    Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010;33:983–90.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. O'Reilly RJ,
    2. Doubrovina E,
    3. Trivedi D,
    4. Hasan A,
    5. Kollen W,
    6. Koehne G
    . Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res 2007;38:237–50.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Bollard CM,
    2. Gottschalk S,
    3. Leen AM,
    4. Weiss H,
    5. Straathof KC,
    6. Carrum G,
    7. et al.
    Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007;110:2838–45.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Hunder NN,
    2. Wallen H,
    3. Cao J,
    4. Hendricks DW,
    5. Reilly JZ,
    6. Rodmyre R,
    7. et al.
    Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698–703.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Johnson LA,
    2. Morgan RA,
    3. Dudley ME,
    4. Cassard L,
    5. Yang JC,
    6. Hughes MS,
    7. et al.
    Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535–46.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Flaherty KT,
    2. Puzanov I,
    3. Kim KB,
    4. Ribas A,
    5. McArthur GA,
    6. Sosman JA,
    7. et al.
    Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809–19.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Hodi FS,
    2. O'Day SJ,
    3. McDermott DF,
    4. Weber RW,
    5. Sosman JA,
    6. Haanen JB,
    7. et al.
    Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Weber J,
    2. Atkins M,
    3. Hwu P,
    4. Radvanyi L,
    5. Sznol M,
    6. Yee C
    . White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 2011;17:1664–73.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Yvon E,
    2. Del Vecchio M,
    3. Savoldo B,
    4. Hoyos V,
    5. Dutour A,
    6. Anichini A,
    7. et al.
    Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res 2009;15:5852–60.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 17 (13)
July 2011
Volume 17, Issue 13
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Getting Personal with Melanoma
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Getting Personal with Melanoma
Helen Heslop
Clin Cancer Res July 1 2011 (17) (13) 4189-4191; DOI: 10.1158/1078-0432.CCR-11-0841

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Getting Personal with Melanoma
Helen Heslop
Clin Cancer Res July 1 2011 (17) (13) 4189-4191; DOI: 10.1158/1078-0432.CCR-11-0841
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Disclosure of Potential Conflicts of Interest
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • “Magic Bullets” for Molecular Targeting of Cancer
  • CDK12 and Immune Microenvironment
  • T-Cell Senescence and Lung Cancer Immunotherapy Resistance
Show more CCR Translations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement